MYNVAX

mynvax-logo

Mynvax is an Indian-based biotech startup that develops next-generation vaccines for influenza. In addition, the technology allows for very rapid, large-scale, and low-cost production of vaccines that could potentially be used to protect people when there is a pandemic. Mynvax, which was incubated at the Indian Institute of Science, was founded in 2017 by Raghavan Varadarajan and Gautham Nadig.

#SimilarOrganizations #People #Financial #Website #More

MYNVAX

Social Links:

Industry:
Biotechnology Health Care

Founded:
2017-05-05

Address:
Bangalore, Karnataka, India

Country:
India

Website Url:
http://www.mynvax.com

Total Employee:
1+

Status:
Active

Total Funding:
4.13 M USD


Similar Organizations

innovative-cellular-therapeutics-logo

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.

metis-therapeutics-logo

METiS Therapeutics

METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.

novellus-logo

Novellus

Novellus is a biotechnology company working to develop engineered cellular medicines.

paxvax-logo

PaxVax

PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.

Current Employees Featured

not_available_image

Gautam Nadig
Gautam Nadig Founder @ Mynvax
Founder

not_available_image

Raghavan Varadarajan
Raghavan Varadarajan Founder @ Mynvax
Founder

Founder


not_available_image

Gautam Nadig

not_available_image

Raghavan Varadarajan

Investors List

accel_image

Accel

Accel investment in Series A - Mynvax

kotak-investment-advisors_image

Kotak Investment Advisors

Kotak Investment Advisors investment in Series A - Mynvax

1crowd_image

1Crowd

1Crowd investment in Series A - Mynvax

letsventure_image

LetsVenture

LetsVenture investment in Series A - Mynvax

ajith-sukumaran_image

Ajith Sukumaran

Ajith Sukumaran investment in Angel Round - Mynvax

Official Site Inspections

http://www.mynvax.com

  • Host name: 106.51.79.41.actcorp.in
  • IP address: 106.51.79.41
  • Location: Bengaluru India
  • Latitude: 12.9721
  • Longitude: 77.5933
  • Timezone: Asia/Kolkata
  • Postal: 560002

Loading ...

More informations about "Mynvax"

Mynvax Company Profile 2024: Valuation, Funding

When was Mynvax founded? Mynvax was founded in 2017. Where is Mynvax headquartered? Mynvax is headquartered in Bangalore, India. What is the size of Mynvax? Mynvax has 31 total employees. What industry is Mynvax in? …See details»

Mynvax Private Limited - LinkedIn

Mynvax Private Limited | 4,659 followers on LinkedIn. Efficacious vaccine for respiratory viruses | Mynvax is a pre-clinical stage vaccine biotechnology. Current develop programs include a...See details»

Mynvax Company Profile: Overview and Full News Analysis

Mynvax is a clinical stage vaccine biotechnology company located in Karnataka, India. The company is focused on developing novel, improved, recombinant, thermostable vaccines to …See details»

Our investment in Mynvax

Founded by Prof Raghavan Varadarajan and Dr Gautham Nadig, Mynvax is working on vaccines for respiratory diseases like Covid-19. Accel's investment will help Mynvax move from R&D to …See details»

Indian Institute of Science

A ‘warm’ COVID-19 vaccine candidate being developed by an IISc and Mynvax team was found to trigger a strong immune response and protection in mice and hamster models, in results …See details»

IISc-incubated Mynvax to get funding to bring “warm” Covid …

Mynvax, a vaccine technology startup, incubated by the Society for Innovation and Development (SID) at the Indian Institute of Science, has signed an agreement to raise $4.2 million (₹31 …See details»

New ‘warm vaccine’ is effective against all key coronavirus ... - CSIRO

Jul 26, 2021 · Researchers at the Indian Institute of Science (IISc) and biotech start-up Mynvax have been developing a new ‘warm’ vaccine candidate that does not require refrigeration. …See details»

'Warm vaccine' shows immune response against SARS-CoV-2 …

Jul 16, 2021 · Several formulations of Mynvax made antibodies effectively in the animal experiments, neutralising the Alpha, Beta, Gamma and Delta variants of SARS-CoV-2, they …See details»

Firm’s warm vax gets $4.2 million funding boost - Times of India

Jul 20, 2021 · Mynvax, a vaccine technology startup, on Monday said it has signed definitive agreements to raise $4.2 million — around Rs 31 crore — in its Series A round of financing led …See details»

IISc firm Mynvax raises $4.2 million to bring the ‘warm vaccine’ to ...

Jul 19, 2021 · BENGALURU: Mynvax, a vaccine technology startup incubated by the Society for Innovation and Development (SID) at the Indian Institute of Science, on Monday said it has …See details»

Bengaluru-based Mynvax laboratories’ ‘warm’ COVID-19 ... - The …

Apr 17, 2022 · The ‘warm’ vaccine developed by the Bengaluru-based Mynvax laboratories, a company incubated at the Indian Institute of Science Bangalore, is unique among existing …See details»

Pre-clinical evaluation of new 'heat-tolerant' COVID-19 vaccine, …

Jul 15, 2021 · We contributed to the pre-clinical assessment of Mynvax – a heat-tolerant COVID-19 vaccine developed by the Indian Institute of Science and biotech start-up company …See details»

IISc-incubated technology startup Mynvax raises Rs 31 crore for …

Jul 19, 2021 · Mynvax, a vaccine technology startup at the Indian Institute of Science (IISc) which is developing a Covid-19 warm vaccine, has raised crores in funding. In an announcement on …See details»

Design of a highly thermotolerant, immunogenic SARS-CoV-2 …

Nov 23, 2020 · We describe a monomeric, glycan-engineered RBD protein fragment that is expressed at a purified yield of 214 mg/l in unoptimized, mammalian cell culture and, in …See details»

Vaccine that could work against new Covid variants in pipeline

Jan 12, 2024 · Bengaluru: The Indian Institute of Science (IISc) together with Bengaluru-based startup Mynvax, a Biotechnology company, has come up with a Covid vacc.See details»

Monomer vaccines fare better than trimers against SARS-CoV-2

Apr 13, 2022 · Scientists at the Indian Institute of Science and Mynvax Private Limited, in Bangalore, prepared the vaccines using a specific part of the spike protein of SARS-CoV-2. …See details»

India’s ‘warm’ vaccine candidate effective against Delta, Omicron ...

Apr 16, 2022 · The vaccine candidate, by the Indian Institute of Science (IISc) in Bengaluru and biotech start-up company Mynvax, uses a part of the viral spike protein called the receptor …See details»

Press Release:Press Information Bureau

Sep 14, 2024 · These include collaborative research over a small molecule for multiple myeloma with Aurigene Oncology Limited, partnering for Zika vaccine development with Indian …See details»

Mynvax vaccine I IISc’s ‘warm’ COVID-19 vaccine effective against …

Jul 16, 2021 · New Delhi: Indian Institute of Science (IISc) developed ‘warm’ Covid-19 vaccine has proven effective against all current SARS-CoV-2 variants of concern, a study conducted …See details»

Mynvax - Company Profile - Tracxn

Nov 19, 2024 · Mynvax - Developer of novel recombinant vaccines to fight the human influenza virus and COVID19. Raised a total funding of $9.82M over 4 rounds from 56 investors. Valued …See details»

linkstock.net © 2022. All rights reserved